NeuroOne Medical Technologies Corporation reported its earnings for the three months ended December 31, 2025. The company generated no license revenue for the period, following license revenue of USD 3.0 million in the prior year period, which was related to the distribution license granted to Zimmer for the OneRF Product in October 2024. Selling, general and administrative expenses were USD 1.9 million for the quarter. Cost of product revenue included royalty fees of approximately USD 38,000 during the period. The company noted that while regulatory clearance was received to expand the use of its Evo sEEG electrode technology for up to 30 days, commercial sales of the sEEG electrodes and OneRF Ablation System are expected to take time to become a significant source of liquidity. NeuroOne expects to meet its short- and long-term obligations through cash on hand and revenue from commercial sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-016860), on February 17, 2026, and is solely responsible for the information contained therein.